Unity Biotechnology Inc. (9U90)
XBER 
Summary
UBX Stock Down 29% on Mixed Results From Phase II Eye Disease Study
UNITY Biotechnology stock loses 29% as the mid-stage DME study of the lead candidate, UBX1325, fails to achieve statistical significance for the primary goal.
Unity Biotechnology Unveils Mixed Data From Study For Diabetes-Related Blindness, Stock Falls
Unity Biotechnology, Inc. UBX stock plummeted on Monday after the company released results from its latest study.
UNITY Biotechnology (UBX) Upgraded to Buy: Here's What You Should Know
UNITY Biotechnology (UBX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Unity Biotechnology Inc. Profile
| Biotechnology Industry | Healthcare Sector | Anirvan Ghosh CEO | XBER Exchange | US91381U2006 ISIN |
| US Country | 16 Employees | - Last Dividend | 20 Oct 2022 Last Split | 3 May 2018 IPO Date |
Overview
Unity Biotechnology, Inc. is at the forefront of biotechnological innovations, dedicated to the development of novel therapeutics aimed at decelerating, halting, or reversing the aging process and its associated diseases. Initially established as Forge, Inc., the organization rebranded to Unity Biotechnology, Inc. in January 2015, marking a pivotal shift in its mission towards addressing aging-related ailments. Since its inception in 2009, Unity has positioned itself as a pivotal player in the biotech industry, with its headquarters in South San Francisco, California. The company's vital research focuses on creating drug solutions that tackle diseases of aging, with particular emphasis on ophthalmologic conditions.
Products and Services
UBX1325
This leading drug candidate showcases Unity Biotechnology's innovative efforts in combating age-related eye diseases. Currently in phase II of clinical trials, UBX1325 is designed to treat diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. Through targeting mechanisms believed to contribute to these conditions, UBX1325 exemplifies the company's dedication to halting age-related degenerative processes.
UBX1967
Another testament to Unity's commitment to ophthalmological innovation, UBX1967, is under development to address a spectrum of eye diseases. This potential therapeutic aligns with the company's focus on providing solutions that improve the quality of life for individuals suffering from vision impairment and degradation due to aging.
UBX2050
A human anti-Tie2 agonist monoclonal antibody, UBX2050, is Unity's pivotal initiative in the realm of age-related eye diseases. By harnessing the power of targeted antibody therapy, UBX2050 aims to offer a novel approach in treating conditions that lead to vision loss, aligning with Unity's overarching goal of reversing the effects of aging on the human body.
UBX2089
Expanding beyond ophthalmology, UBX2089 represents Unity's venture into neurology, addressing the multifaceted impact of aging. This drug candidate, based on the a-Klotho hormone, illustrates the company's innovative approach to tackling age-related neurological conditions, offering hope for therapies that extend beyond vision, encompassing broader aspects of aging and health.
Contact Information
